Trade names Omnipaque, others | ATC code V08AB02 (WHO) | |
 | ||
AHFS/Drugs.com Micromedex Detailed Consumer Information Pregnancy
category US: B (No risk in non-human studies) Routes of
administration intrathecal, intravascular, by mouth, intracavital, rectal Legal status In general: ℞ (Prescription only) | ||
Iohexol, sold under the trade names Omnipaque among others, is a contrast agent used during X-rays. This includes when visualizing arteries, veins, ventricles of the brain, the urinary system, and joints, as well as during computer tomography (CT scan). It is given by mouth, injection into a vein, or into a body cavity.
Contents
Side effects include vomiting, skin flushing, headache, itchiness, kidney problems, and low blood pressure. Less commonly allergic reactions or seizures may occur. It should not be used by those who have a iodine allergy. Use in the later part of pregnancy may cause hypothyroidism in the baby. Iohexol is an iodinated non-ionic radiocontrast agent. It is in the low osmolar family.
Iohexol was approved for medical use in 1985. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is about 10.99 USD per 50 ml vial. In the United States a dose costs 50 to 100 USD.
Chemistry
The osmolality of iohexol ranges from 322 mOsm/kg—approximately 1.1 times that of blood plasma—to 844 mOsm/kg, almost three times that of blood. Despite this difference, iohexol is still considered a low-osmolality contrast agent; the osmolality of older agents, such as diatrizoate, may be more than twice as high.
Names
It is sold under the brand names Omnipaque and Exypaque. It is also sold as a density gradient medium under the names Accudenz, Histodenz and Nycodenz.
Formulations
It is available in various concentrations, from 140 to 350 milligrams of iodine per milliliter.